A recent study shows the OCRDs, especially those that are more body-focused, have the potential to emerge or worsen during pregnancy and the postpartum, leading to high levels of comorbid depression and functional impairment.
Despite the unequivocal benefits of folic acid supplementation and recommendations urging all women of reproductive age to take folic acid supplements, preconceptual use of folic acid has not increased substantially.
This task force does not recommend universal, instrument-based screening for perinatal depression because we lack clear evidence that screening improves outcomes.
Cannabis use, as well as use of benzodiazepines and sedative-hypnotic medications, was more common in women with depression.
Second-generation antipsychotic medications associated with high metabolic risk (quetiapine, olanzapine, and clozapine) were associated with increased risk of gestational diabetes; other antipsychotics were not.
Fetal brain development is altered by elevated maternal distress and has adverse infant social-emotional and cognitive outcomes.
More that half of women with bipolar disorder relapsed during pregnancy.
This initiative will gauge mental health clinicians’ experience with and attitudes around treating pregnant women with mental and substance use disorders in order to identify training gaps.
Many women experience depression during pregnancy. What is the best way to identify these women?
This review suggests that CBT can be used to target depression during pregnancy and can be delivered using a digital platform.
